275 related articles for article (PubMed ID: 36499382)
41. Suppression of inflammation-induced lung cancer cells proliferation and metastasis by exiguaflavanone A and exiguaflavanone B from
Arjsri P; Srisawad K; Semmarath W; Umsumarng S; Rueankham L; Saiai A; Rungrojsakul M; Katekunlaphan T; Anuchapreeda S; Dejkriengkraikul P
Front Pharmacol; 2023; 14():1243727. PubMed ID: 38026959
[No Abstract] [Full Text] [Related]
42. Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy.
Chehelgerdi M; Behdarvand Dehkordi F; Chehelgerdi M; Kabiri H; Salehian-Dehkordi H; Abdolvand M; Salmanizadeh S; Rashidi M; Niazmand A; Ahmadi S; Feizbakhshan S; Kabiri S; Vatandoost N; Ranjbarnejad T
Mol Cancer; 2023 Nov; 22(1):189. PubMed ID: 38017433
[TBL] [Abstract][Full Text] [Related]
43. Proton therapy (PT) combined with concurrent chemotherapy for locally advanced non-small cell lung cancer with negative driver genes.
Jin Y; Shimizu S; Li Y; Yao Y; Liu X; Si H; Sakurai H; Xiao W
Radiat Oncol; 2023 Nov; 18(1):189. PubMed ID: 37974211
[TBL] [Abstract][Full Text] [Related]
44. The Riddle of the Sphinx: Progress in Leptomeningeal Metastasis of Non-Small Cell Lung Cancer.
Zhao Y; Yu L; Wang L; Wu Y; Chen H; Wang Q; Wu Y
Clin Med Insights Oncol; 2023; 17():11795549231205206. PubMed ID: 37915530
[TBL] [Abstract][Full Text] [Related]
45. Epigenetic regulation in lung cancer.
Ramazi S; Daddzadi M; Sahafnejad Z; Allahverdi A
MedComm (2020); 2023 Dec; 4(6):e401. PubMed ID: 37901797
[TBL] [Abstract][Full Text] [Related]
46. Unveiling Potential Targeted Therapeutic Opportunities for Co-Overexpressed Targeting Protein for Xklp2 and Aurora-A Kinase in Lung Adenocarcinoma.
Mukherjee A; Yadav PH; Mukunthan KS
Mol Biotechnol; 2023 Sep; ():. PubMed ID: 37768502
[TBL] [Abstract][Full Text] [Related]
47. Protein Z modulates the metastasis of lung adenocarcinoma cells.
Peng J; Yang KY; Li H; Zheng SS; Pan XY
Open Life Sci; 2023; 18(1):20220667. PubMed ID: 37528887
[TBL] [Abstract][Full Text] [Related]
48. Advances in Genomic Data and Biomarkers: Revolutionizing NSCLC Diagnosis and Treatment.
Restrepo JC; Dueñas D; Corredor Z; Liscano Y
Cancers (Basel); 2023 Jul; 15(13):. PubMed ID: 37444584
[TBL] [Abstract][Full Text] [Related]
49. Comparison between Three Different Techniques for the Detection of EGFR Mutations in Liquid Biopsies of Patients with Advanced Stage Lung Adenocarcinoma.
Casula M; Pisano M; Paliogiannis P; Colombino M; Sini MC; Zinellu A; Santeufemia D; Manca A; Casula S; Tore S; Lobrano R; Sardinian Lung Cancer Study Group ; Cossu A; Palmieri G
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047382
[TBL] [Abstract][Full Text] [Related]
50. Nanoparticles overcome adaptive immune resistance and enhance immunotherapy
Zhang X; Wang X; Hou L; Xu Z; Liu Y; Wang X
Front Pharmacol; 2023; 14():1130937. PubMed ID: 37033636
[TBL] [Abstract][Full Text] [Related]
51. Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer.
Remon J; Pignataro D; Novello S; Passiglia F
Cancer Treat Rev; 2021 Apr; 95():102178. PubMed ID: 33743408
[TBL] [Abstract][Full Text] [Related]
52. Clinical features of Bim deletion polymorphism and its relation with crizotinib primary resistance in Chinese patients with ALK/ROS1 fusion-positive non-small cell lung cancer.
Zhang L; Jiang T; Li X; Wang Y; Zhao C; Zhao S; Xi L; Zhang S; Liu X; Jia Y; Yang H; Shi J; Su C; Ren S; Zhou C
Cancer; 2017 Aug; 123(15):2927-2935. PubMed ID: 28346673
[TBL] [Abstract][Full Text] [Related]
53. Non-Small Cell Lung Cancer Targeted Therapy: Drugs and Mechanisms of Drug Resistance.
Wu J; Lin Z
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499382
[TBL] [Abstract][Full Text] [Related]
54. VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small-cell lung cancers.
Watanabe H; Ichihara E; Kayatani H; Makimoto G; Ninomiya K; Nishii K; Higo H; Ando C; Okawa S; Nakasuka T; Kano H; Hara N; Hirabae A; Kato Y; Ninomiya T; Kubo T; Rai K; Ohashi K; Hotta K; Tabata M; Maeda Y; Kiura K
Cancer Sci; 2021 May; 112(5):1853-1864. PubMed ID: 33410241
[TBL] [Abstract][Full Text] [Related]
55. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
Sgambato A; Casaluce F; Maione P; Gridelli C
Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
[TBL] [Abstract][Full Text] [Related]
56. Resistance Mechanisms to Targeted Therapies in
McCoach CE; Le AT; Gowan K; Jones K; Schubert L; Doak A; Estrada-Bernal A; Davies KD; Merrick DT; Bunn PA; Purcell WT; Dziadziuszko R; Varella-Garcia M; Aisner DL; Camidge DR; Doebele RC
Clin Cancer Res; 2018 Jul; 24(14):3334-3347. PubMed ID: 29636358
[No Abstract] [Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
